BICSTar: Biktarvy® shows high efficacy against HIV in real-world setting

Gilead’s Biktarvy demonstrated a consistently high efficacy of over 95 percent in analyses of the ongoing real-world cohort BICSTaR study.

Additional information, at the following link: https://www.europeanpharmaceuticalreview.com/news/164962/biktarvy-shows-high-efficacy-against-hiv-in-real-world-setting/